Evidence map›Paper›PMID 42040604›Full record

ArticleFrontiers in medicine2026

Real-world effectiveness of vonoprazan-based regimen versus rabeprazole-based dual therapy for

Yurong Huang, Juan Zheng, Zhengyi Yang, Daili Li, Hua Wu, Wenzhong Chen, Wenjuan Wang, Min Gan, Changmei Shi, Dongmei Xie and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yurong Huang *Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Juan Zheng *Department of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Zhengyi YangDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Daili LiDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Hua WuDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Wenzhong ChenDepartment of Gastroenterology, Tongren People's Hospital, Tongren, Guizhou, China.
Wenjuan WangDepartment of Gastroenterology, Xingyi People's Hospital, Xingyi, Guizhou, China.
Min GanDepartment of Gastroenterology, Anshun People's Hospital, Anshun, Guizhou, China.
Changmei ShiDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Dongmei XieDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Canyu ZhanDepartment of Gastroenterology, Xingyi People's Hospital, Xingyi, Guizhou, China.
Gengqing SongDepartment of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, United States.
Jie YangDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: While vonoprazan-amoxicillin dual therapy has achieved > 90% eradication rates for Methods: This retrospective analysis (April 2022-November 2023) included 598 Results: After excluding patients lost to follow-up and those with poor compliance, the eradication rates were 87.2% (Group A), 81.4% (Group B), 82.1% (Group C), and 71.5% (Group D). Group A achieved a significantly higher eradication rate than Group D ( Conclusion: In the high-resistance environment of Guizhou, vonoprazan-based regimens are significantly more effective than traditional rabeprazole-based dual therapy, yet they face unique regional challenges. The failure of q.d. vonoprazan dosing and the sub-90% success rate of b.i.d. dosing suggest that in regions with extreme resistance and high ethnic diversity, standard global protocols may require further optimization.

Indexed as

dual therapyefficacyHelicobacter pylorirabeprazolevonoprazan

Identifiers

PMID42040604
PMCPMC13105932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.